Effects of ursodeoxycholic acid in reducing recurrence of choledocholithiasis: a randomized control trial

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20231102009

Enrollment

Registered

2023-11-02

Start date

2023-04-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent CBD stones in patients who were diagnosed with CBD stones and undergone complete removal of CBD stones by endoscopic procedure. Choledocholithiasis common bile duct stones Ursodeoxycholic acid

Interventions

Receive oral Ursodeoxycholic acid 15 mg/kg/day ,Receive placebo that looks identical to Ursodeoxycholic acid

Active Comparator Drug,Placebo Comparator Drug

Ursodeoxycholic acid group,Placebo group

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Undergone complete removal of CBD stones by endoscopic procedure 2. Ability and willingness to give informed consent

Exclusion criteria

Exclusion criteria: 1. Residual CBD stone 2. A history of hypersensitivity to UDCA 3. Current treatment with another bile acid formulation 4. Pregnant women 5. Individuals who are diagnosed with cancer

Design outcomes

Primary

Measure	Time frame
Recurrence rate of CBD stones at 6, 12, 18 months after intervention Endoscopic ultrasonography	—

Secondary

Measure	Time frame
Adverse effects of Ursodeoxycholic acid at 3, 6, 12, 18 months after intervention Patient reported outcome using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactFaampai Nantamanop

Royal Thai Army Medical Department

n.faampai@gmail.com66897734542

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026